Otlertuzumab

Drug Profile

Otlertuzumab

Alternative Names: Humanised Anti-CD37 therapeutic - Emergent Biosolutions; TRU-016

Latest Information Update: 16 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Emergent BioSolutions
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Apoptosis stimulants; CD37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
  • 10 Jun 2015 Phase-II development for Chronic lymphocytic leukaemia is ongoing in the US
  • 10 Dec 2013 Interim efficacy and adverse events data from a phase Ib and a phase Ib/II trial in Chronic lymphocytic leukaemia presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2013) (9157267 & 9157350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top